Literature DB >> 11202906

The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase.

A K Roshak1, E A Capper, C Imburgia, J Fornwald, G Scott, L A Marshall.   

Abstract

Entry into mitosis by mammalian cells is triggered by the activation of the cdc2/cyclin B holoenzyme. This is accomplished by the specific dephosphorylation of key residues by the cdc25C phosphatase. The polo-like kinases are a family of serine/threonine kinases which are also implicated in the control of mitotic events, but their exact regulatory mechanism is not known. Recently, a Xenopus homologue, PLX1, was reported to phosphorylate and activate cdc25, leading to activation of cdc2/cyclin B. Jurkat T leukemia cells were chemically arrested and used to verify that PLK protein expression and its phosphorylation state is regulated with respect to cell cycle phase (i.e., protein is undetectable at G1/S, accumulates at S phase and is modified at G2/M). Herein, we show for the first time that endogenous human PLK protein immunoprecipitated from the G2/M-arrested Jurkat cells directly phosphorylates human cdc25C. In addition, we demonstrate that recombinant human (rh) PLK also phosphorylates rhcdc25C in a time- and concentration-dependent manner. Phosphorylation of endogenous cdc25C and recombinant cdc25C by PLK resulted in the activation of the phosphatase as assessed by dephosphorylation of cdc2/cyclin B. These data are the first to demonstrate that human PLK is capable of phosphorylating and positively regulating human cdc25C activity, allowing cdc25C to dephosphorylate inactive cdc2/cyclin B. As this event is required for cell cycle progression, we define at least one key regulatory mode of action for human PLK in the initiation of mitosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11202906     DOI: 10.1016/s0898-6568(00)00080-2

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  60 in total

1.  Scytonemin--a marine natural product inhibitor of kinases key in hyperproliferative inflammatory diseases.

Authors:  C S Stevenson; E A Capper; A K Roshak; B Marquez; K Grace; W H Gerwick; R S Jacobs; L A Marshall
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

2.  The Polo-like kinase PLKA in Aspergillus nidulans is not essential but plays important roles during vegetative growth and development.

Authors:  Klarita Mogilevsky; Amandeep Glory; Catherine Bachewich
Journal:  Eukaryot Cell       Date:  2011-12-02

3.  PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins.

Authors:  Benjamin Deneen; Scott M Welford; Thu Ho; Felicia Hernandez; Irwin Kurland; Christopher T Denny
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

4.  Female infertility in PDE3A(-/-) mice: polo-like kinase 1 (Plk1) may be a target of protein kinase A (PKA) and involved in meiotic arrest of oocytes from PDE3A(-/-) mice.

Authors:  Weixing Shen; Faiyaz Ahmad; Steven Hockman; John Ma; Hitoshi Omi; Nalini Raghavachari; Vincent Manganiello
Journal:  Cell Cycle       Date:  2010-12-01       Impact factor: 4.534

5.  An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication.

Authors:  Syed Mohd Danish Rizvi; Abdulaziz Arif A Alshammari; Waleed Abdullah Almawkaa; Abo Bakr F Ahmed; Ahmed Katamesh; Ahmed Alafnan; Tariq J Almutairi; Rakan F Alshammari
Journal:  3 Biotech       Date:  2019-02-09       Impact factor: 2.406

6.  Calcium-dependent inhibition of polo-like kinase 3 activity by CIB1 in breast cancer cells.

Authors:  Meghna U Naik; Ngoc T Pham; Kristin Beebe; Wei Dai; Ulhas P Naik
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

7.  Overexpression of Plk1 promotes malignant progress in human esophageal squamous cell carcinoma.

Authors:  Chunling Zhao; Lei Gong; Wentong Li; Limei Chen
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

8.  Polo-like kinase 1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass.

Authors:  Gina Chun; Dongsoon Bae; Kristen Nickens; Travis J O'Brien; Steven R Patierno; Susan Ceryak
Journal:  Carcinogenesis       Date:  2010-01-20       Impact factor: 4.944

Review 9.  Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy.

Authors:  Yingmei Wang; Ping Ji; Jinsong Liu; Russell R Broaddus; Fengxia Xue; Wei Zhang
Journal:  Mol Cancer       Date:  2009-02-13       Impact factor: 27.401

10.  Distinct pools of cdc25C are phosphorylated on specific TP sites and differentially localized in human mitotic cells.

Authors:  Celine Franckhauser; Daria Mamaeva; Lisa Heron-Milhavet; Anne Fernandez; Ned J C Lamb
Journal:  PLoS One       Date:  2010-07-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.